| [ Summary ] |
Abnormalities in bone mineral metabolism have been recognized as one of many the chronic complications of type 2 diabetes mellitus, such as a high frequency of bone fractures and enlongated bone healing after fractures. We reported on a functional uncoupling relationship between osteoblasts and osteoclasts, ie decreased osteoblastic bone formation and increased osteoclastic bone resorption, which occurrs in patients with type 2 diabetes mellitus and that this phenomenon could lead to osteopenia. We have decided to measure specific bone metabolic markers in serum and / or urine in addition to bone mineral content in order to evaluate the pathophysiological mechanism of altered bone metabolism in diabetes mellitus in order to choose the proper treatment strategy. At this time, we can measure many markers, such as following ; bone resorption, tertarate resistant acid phosphatase (TRACP), deoxypyridinoline (DPD), cross-linked N-telopeptides of type I collagen (NTX) and cross-linked C-teropeptides of type I collagen (CTX), and markers of bone formation, as well as those for bone alkaline phosphatase (BAP), C-terminal propeptide of type I procollagen (PICP), N-terminal propeptide of type I procollagen (PINP) and osteocalcin (OC). By following the guidelines edited by the Japan Osteoporosis Society, we can utilize these markers for the clinical fields, especially for the treatment of osteopenia and osteoporosis. |